EV/EBITDA Multiple: Lumos Pharma Corp (LUMO)
Lumos Pharma, Inc. (LUMO) minimizes scientific risks by developing therapies for children with growth anomalies, securing leadership within a niche segment. Strong physician confidence is driven by the efficacy of their oral hormonal drug. The available price action trend based on the EV/EBITDA metric stands at , while business success remains contingent upon drug trial outcomes and a stable capital reserve.
Lumos Pharma Inc (LUMO) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Lumos Pharma, Inc.|LUMO - Long-Term Debt to Equity|Short-Term Debt to Equity lumos-pharma.com|LUMO - Company Cumulative Debt|Debt to Book Capitalization Ratio Lumos Pharma, Inc.|LUMO - Company Long-Term Debt|Company Short-Term Debts Lumos Pharma|Quick Liquidity lumos-pharma.com
- net income and valuation multiples indicators:
LUMO - Net Financial Result|Expected Profit Lumos Pharma, Inc.|LUMO - Price to Earnings Ratio|Future Price to Earnings Lumos Pharma|LUMO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Lumos Pharma|LUMO - Operating profit EBITDA|Earnings per share for the last twelve months Lumos Pharma|LUMO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months lumos-pharma.com|LUMO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Lumos Pharma, Inc.
- issuer revenue and sales details:
Initial company analysis:LUMO (Lumos Pharma, Inc.)
It is critical for investors to find an equilibrium between operational returns and the debt load of capital. The Lumos Pharma, Inc. (LUMO) model, utilizing outsourced production, minimizes capital expenditures, rendering the company a flexible scientific structure. An analysis of the business's EV/EBITDA ratio allows for a comparison of the total enterprise value against its ability to generate earnings before interest, taxes, depreciation, and amortization, thereby determining the asset's real financial stability.
Who Lumos Pharma, Inc. competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio Aardvark Therapeutics Inc AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences, Inc. SGMT|BioAge - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomea Fusion Corp - EV/EBITDA Multiple|QNCX - EV/EBITDA Multiple|GUTS: EV/EBITDA Multiple|VTVT (vTv Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agape ATP Corp.|PLUR: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Synlogic, Inc. (SYBX)|Enterprise Value to EBITDA Ratio Lipocine Corp LPCN|EV/EBITDA Multiple MTNB (Matinas BioPharma Holdings, Inc.)|Spruce Biosciences (SPRB) - Company Value to EBITDA|GLTO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTCX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation
